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Migration  of lymphocytes into inflammatory  sites requires their adhesion to the vascular en- 
dothelium and subendothelial extracellular matrix (ECM). The ensuing penetration of the ECM 
is associated with the expression of ECM-degrading enzymes, such as endo-B-D glucuronidase 
(heparanase), which cleaves heparan sulfate (HS) proteoglycans. We now report that, depending 
on the local pH, a mammalian heparanase can function either as an enzyme or as an adhesion 
molecule. At relatively acidified  pH conditions,  heparanase performs as an enzyme, degrading 
HS. In contrast, at the hydrogen ion concentration of a quiescent tissue, heparanase binds specifically 
to HS molecules without degrading them, and thereby anchors CD4 + human T lymphocytes. 
Thus, the local state of a tissue can regulate the activities of heparanase and can determine whether 
the molecule will function  as an enzyme or as a proadhesive molecule. 
ukocyte-mediated inflammatory  reactions  and immune 
surveillance require the activation ofleukocytes by specific 
antigens, cytokines, and chemokines, and the ensuing extrava- 
sation of circulating immune cells from blood vessels to sites 
of inflammation (1-3). The recognition and the subsequent 
interactions of the infiltrating immune cells,  such as CD4 + 
T lymphocytes, with glycoproteins of the subendothelial base- 
ment membrane and extracellular matrix (ECM) is mediated 
primarily by integrin receptors of the/~1  subfamily (1).  In 
addition, the physiologically programmed migration of T cells 
is associated with the secretion of various matrix-degrading 
enzymes, such as endo-fl-D glucuronidase (heparanase)  (4-6). 
Naive CD4 § T  lymphocytes respond to activation by syn- 
thesizing heparanase de novo, whereas memory T  cells re- 
lease heparanase from preformed stores within minutes of con- 
tact with antigen (4). The cell surface-, basement membrane-, 
or ECM-associated heparan sulfate (HS) proteoglycans, which 
serve as substrates for the catalytic activity of heparanase,  de- 
termine the self-assembly and insolubility of the ECM, stabilize 
the matrix structure,  and maintain  the matrix integrity by 
interacting with ECM glycoproteins (4). The HS molecules 
also affect the  proliferation  of immune  cells  (7)  and bind 
growth factors and cytokines (8, 9). Herein,  we examined 
whether the performance of heparanase is affected by physio- 
logical alterations in the environment,  specifically,  whether 
in addition  to displaying an enzymatic activity, heparanase 
can also regulate the accumulation ofT cells in inflamed tissues. 
Materials and Methods 
Isolation and Purification of Mammalian Heparanase.  Heparanase 
was purified from human placenta by a modification of a previously 
described method (10). Briefly, human placentas were homogenized 
and suspended in 10 mM phosphate-citrate  buffer (PCB; pH 6.0), 
sonicated, and centrifuged  (3000 g, 4~  15 min).  Proteins were 
precipitated with 35-55% AmSO4, resuspended in 10 mM PCB 
containing 0.1 M NaCl, and dialyzed against the same buffer. The 
dialyzed material was then subjected to cation exchange chroma- 
tography on CM-Sepharose (Kabi-Pharmacia, Stockholm, Sweden) 
equilibrated with PCB (pH 6.0) containing 0.1% 3-([3-cholamido- 
propyl]-dimethylammonio)-l-propane-sulfonate  (CHAPS).  The 
column was subjected to a 0.3-1.1 M NaC1 gradient; heparanase 
eluted at 0.6-0.7 M NaC1. The enzymatically active heparanase 
fractions were pooled, dialyzed, and applied to heparin-Sepharose 
(Kabi-Pharmacia; 10 mM phosphate-citrate containing 0.2 M NaC1, 
0.1% CHAPS, pH 7.2). Upon elution, active fractions eluted with 
a NaC1 gradient (0.35-1.1 M) at 0.7-0.8 M NaC1. The pooled frac- 
tions were adjusted to 1 M NaC1 in 10 mM PCB (pH 6.0; 0.1% 
CHAPS) and applied to a Con A-Sepharose column (Sigma Chem- 
ical Co., St. Louis, MO). Heparanase was eluted with the same 
buffer containing  0.25 M or-methyl mannoside (Sigma Chemical 
Co.), dialyzed, and subjected to fast protein liquid chromatography 
(FPLC) Mono-S cation e~hange chromatography. Purified heparanase 
was eluted at 0.7 M NaC1 of the NaC1 gradient (0.25-1 M NaC1). 
Iodination of Placental Heparanase.  Purified heparanase (20 #1) 
was added to 60 #1 of 0.2 M sodium phosphate, pH 7.2, containing 
1 #Ci NamI and incubated (45 s, 22~  with chloramine T (10 
#1 of 1 mg/ml). The reaction was terminated by the addition of 
1929  J. Exp. Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/95/05/1929/06 $2.00 
Volume 181  May 1995  1929-1934 0.05% Na-metabisulfide (50/A) and 10 mM KI (50/A). The reac- 
tion mixture was then applied onto a 0.3 ml heparin-Sepharose 
column equilibrated with 0.2 M NaC1 in 20 mM phosphate buffer, 
pH 7.2.  The column was washed with  the same buffer, and the 
nSI-heparanase  was eluted with  PCB  (1.5  ml) containing  1.1  M 
NaC1, 0.3%  CHAPS,  and 0.2%  gelatin.  The specific activity of 
the 12SI-heparanase was 6-7  x  104 cpm/ng, its enzymatic activity 
was confirmed, and the labeled material was stored at  -  70~  until 
used. 
Analysis  of  Helmranase-induced  ECM Degradation.  To obtain radio- 
labeled, cell-free ECM, bovine corneal endothelial ceils were plated 
in flat-bottomed microtiter plates (Becton Dickinson & Co., Ruther- 
ford, NJ) and maintained as previously described (5, 11, 12), except 
that  5%  dextran  T-40  was  included  in  the  growth  medium. 
Na2[3ss]o4  (40/zCi/ml;  Amersham Corp., Amersham, UK) was 
added 3 and 7 d after seeding. 6-8 d after the ceils reached confluence, 
the cell layer was dissolved by exposure (3 rain,  22~  to 0.5% 
(vol/vol)  Triton  X-100  and  0.025  N  NH4OH  in  PBS, and  the 
plates were washed extensively with PBS. This procedure resulted 
in the underlying ECM being left intact,  firmly attached to the 
entire area of the wells,  free of cellular debris,  and >85%  of the 
total  ECM-bound  3sS was  incorporated  into  HS  proteoglycans. 
The purified heparanase was incubated (different pHs, 37~  with 
3sS-labeled ECM (12). The supernatants were then collected, cen- 
trifuged (10,000 g, 5 min, 4~  and 0.5-ml aliquots of the super- 
natants were applied to Sepharose 6B columns (Sigma Chemical 
Co.; 0.7  x  35 cm) equilibrated with PBS containing 0.1% sodium 
azide.  Fractions (0.2  ml) were collected at a flow rate of 5 ml/h, 
and their radioactivity was determined. The excluded (Vo) and total 
included (Vt) volumes were marked by blue dextran and phenol 
red, respectively. Each experiment was performed at least four times, 
and  the variations in  elution positions  (K,v values)  were always 
<10%. 
Cell Adhesion Assays.  Human  CD4 +  T  cells  were  purified 
from the peripheral blood of healthy donors. The leukocytes were 
isolated on a Ficoil  gradient,  washed,  and incubated at 37~  in 
a 10%  COz-humidified atmosphere. After 2 h,  the nonadherent 
cells were removed and incubated on nylon-wool columns, nonad- 
herent cells were eluted and washed, and the CD4 + T  cells were 
selected (>94% purity) as previously described (13, 14). Adhesion 
ofT cells to ECM-coated wells was assayed as previously described 
(13).  Briefly,  T  cells were labeled  with Na2[SlCr]O4  (Amersham 
Corp.),  washed,  resuspended  in  adhesion  medium  (RPMI-1640 
medium supplemented with 2% BSA,  1 mM Ca  2+ and Mg  2+, 1% 
sodium  pyruvate,  glucose,  and  1%  Hepes),  and  added  to  the 
precoated wells. The microtiter plates were incubated at 37~  for 
30  min in  a  humidified  10%  CO2  incubator  and washed three 
times with PBS to remove nonadherent cells.  The adherent SlCr- 
labeled T  cells were lysed,  and the radioactivity in  the resulting 
supernatants  was determined.  For each experimental group,  the 
results were expressed as the mean percentage (_+SD) of bound T 
cells  in  quadruplicate wells. 
Results and Discussion 
Purification of  Heparanase  and Analysis of  Function.  Hepara- 
nase was isolated from human placenta and purified >3.4  x 
10S-fold by ammonium sulfate precipitation followed by se- 
quential chromatographies on carboxymethyl-, heparin-, and 
Con A-Sepharose columns. The molecular weight, pH depen- 
dency, and substrate specificities of partiaUy purified heparanase 
Figure  1.  Purification of hepara- 
nase and pH dependence of its enzy- 
matic activity. (A) SDS-PAGE anal- 
)'sis of preparations obtained during 
the purification  ofheparanase.  Samples 
were concentrated by precipitation 
with 10% "/'CA  and subjected  to SDS- 
PAGE. (Lane 1 )  35-50%  AmSO4 
precipitate of the placental homoge- 
nate. (Lane 2) Pooled enzymatically 
active fractiom  eluted from CM-Sepha- 
rose. (Lane  3) Pooled active fractions 
eluted from Con A-Sepharose. (B) 
Determination of  the molecular  weight 
of heparanase  by gel filtration. Hepara- 
nase was eluted from Con A-Sepha- 
rose and subjected to FPI.C gel filtra- 
tion on Superdex-75. The heparanase 
activity during  a 1-h incubation at 
37~  was determined for each fraction 
(12). Transferrin,  ovalbumin,  myoglob- 
ulin, and ribonuclease,  with molecular 
masses of 84,  44,  17, and 13.7 kD, 
respectively,  were used as marker pro- 
teins. (C) pH dependency of hepara- 
nase activity. FPLC-purified  heparanase 
was diluted in 10 mM PCB at differ- 
ent pH values, and its ability to re- 
lease low molecular  weight 3sS-labeled 
(peak II) material from the ECM is 
tested. The experiments depicted in 
B and C were performed four times; 
the  variations in  elution  positions 
(K~v values) were <10%. 
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Figure 2.  Analysis of heparanase binding to ECM.  (A). Binding of 
heparanase to wells coated with ECM (I) or BSA ([~). Different concen- 
trations of x2SI-heparanase  were added to the immobilized substrates. After 
2  h  at  37~  unbound lzSI-heparanase was  aspirated,  the wells were 
washed, and bound heparanase was solubilized and quantitated by gamma 
counting. (B) Dissociation  of heparanase from immobilized ECM (11) 
or heparin-Sepharose ([3). Purified heparanase (0.1 #g/ml) was incubated 
(2 h, 37~  in PBS at pH 7.2) with ECM-coated wells or heparin beads 
(0.2 ml), and then the unbound material was removed. The coated wells 
were then incubated with PBS for the time indicated, washed, and the 
remaining ECM-bound 12SI-heparanase  was solubilized and quantitated by 
gamma counting. (C) Blockage by glycosaminoglycans  of 12SI-heparanase 
binding to intact ECM.  Labeled enzyme (0A gg/ml) was preincubated 
(2 h, 37~  pH 7.2) with chondroitin sulfate (Chemicon International, 
Inc., Temecula, CA),  heparin, byaluronic acid, or HS (Sigma Chemical 
Co.) and these mixtures were added to ECM-coated microtiter wells. ECM- 
coated plates were also preincubated (2 h, 37~  pH 7.2) with unlabeled 
heparanase. In A-C, the results are depicted for triplicate wells and are 
isolated from human blood cells, such as lymphocytes, platelets, 
and neutrophils, are similar to those of the purified placental 
enzyme (not shown). To assess the purity of the placental 
heparanase preparations, proteins recovered from the sequen- 
tial purification steps were subjected to SDS-PAGE (Fig.  1 
A),  The final preparation (lane 3) consisted of a "~45-kD 
doublet protein. To verify that heparanase activity was as- 
sociated with this doublet protein, material eluted from Con 
A-Sepharose  was subjected  to FPLC gel filtration, and the 
fractions were tested for heparanase  activity by measuring 
the release of low molecular weight 3sS-labeled HS degra- 
dation products from the ECM-coated wells (12). Maximal 
heparanase activity was associated with the 45-kD protein 
(Fig.  1 B).  Degradation of HS by the purified placental 
heparanase,  as by heparanases  from other cell sources (5), 
was inhibited by preincubation of the enzyme with heparin 
(not shown). 
The pH-dependency of HS degradation by heparanase was 
determined by diluting the enzyme in buffer equilibrated to 
different pH values, incubating the diluted enzyme with 35S- 
ECM, and analyzing the degradation products released into 
the incubation media. At pH 3.4, the heparanase is not ac- 
tive; therefore, no peaks of degraded ECM are observed (Fig. 
1 C). At pH values >6.8 or <5.4, the heparanase exhibited 
little or no activity, as indicated by a low release of low mo- 
lecular  weight  35S-labeled material  characteristic,  of  HS 
degradation fragments (Fig.  1 C; 0.5 <K~v ~<0.8 [peak II, 
fractions  20-35])  (11). The  high  molecular  weight  35S- 
labeled material eluting near the void volume of the column 
(peak I, fractions 5-15, K~v <0.3), probably results from the 
activities of ECM-resident proteases (6). Although the purified 
heparanase is partially active at pH 7.2 or 7.8, maximal re- 
lease of low molecular weight HS fragments occurred at pH 
values ranging from 5.4 to 6.8.  Heparanase  from activated 
CD4 + rat T  cells (5, 12), like HS-specific heparanase from 
tumor cells (15), exhibited its maximal enzymatic activity 
on ECM at pH 6.2-6.8, whereas heparinase counterparts in 
bacteria appear to be optimally active at pH 7.2 (16). Thus, 
heparanase-mediated  cleavage of the HS scaffold of ECM is 
a pH-dependent process, which should be able to occur in 
vivo at the sites of inflammation and tumors where relatively 
acidic pH values have been detected (17-21). 
Heparanase Can Associate with the ECM at Physiological 
pH.  The direct binding of heparanase to ECM or BSA was 
examined by adding dilutions of a25I-heparanase to microtiter 
wells coated with either ECM or BSA. At pH 7.2 and 37~ 
heparanase bound to ECM in a saturable and specific manner 
(Fig. 2 A). However, during a 24-h period, most of the ECM- 
bound heparanase spontaneously dissociated from the ECM 
(Fig. 2 B). The high spontaneous dissociation could be due 
to the activity at 37~  of ECM-associated enzymes (6), such 
representative of four experiments. --C]-, Heparin; --O-, heparan sulfate; 
--I-,  chondroitin  sulfate;  ~-,  hyaluronic  acid; --A-,  unlabeled 
heparanase. 
1931  Gilat et al.  Brief Definitive Report as collagenase IV or plasminogen  activators (22).  If the en- 
zymes deave ECM ligands,  the released heparanase  should 
be intact;  however, if these enzymes also deave the heparanase, 
the conformational intactness of heparanase should be affected. 
Binding of =5I-heparanase  to ECM was inhibited if the ECM 
was preincubated with an excess of unlabeled heparanase,  or 
if the heparanase was preincubated with heparin  or HS (p 
<0.05), but not with hyaluronic acid or chondroitin sulfate 
(Fig.  2  C). 
pH Dependence of the Enzymatic  Activity  of ECM-bound 
Heparanase.  Heparanase  was allowed to bind  to 3sS-ECM 
at a pH that was not permissive to its enzymatic activity (pH 
7.2, 37~  and the unbound enzyme was removed. The pH 
of the medium was then maintained  at 7.2 or decreased to 
6.4,  and  the ensuing  release of degraded  HS was assessed. 
Minimal release of HS degradation fragments occurred if the 
pH was kept at 7.2 (Fig. 3). However, at pH 6.4, the enzy- 
matic activity of heparanase was restored, as indicated by the 
release of HS moieties from the matrix.  Hence, at a physio- 
logical pH  ,  the ECM can retain  heparanase  in an inactive 
form; but if the pH decreases, the temporarily stored enzyme 
(Fig.  2 B)  can regain  its  catalytic activity (Fig.  3). 
The ECM-bound Heparanase Induces the Adhesion of CD4 + 
T Lymphocytes.  Heparanase was diluted in incubation medium 
at different pH levels, added to ECM-coated microtiter wells, 
and  the  unbound  heparanase  was  removed.  51Cr-labeled 
resting  human  CD4 §  T  cells  were added to the precoated 
wells, and their binding to the substrates was assessed.  The 
T cells adhered well to ECM that had been preincubated with 
heparanase at pH 7.2-7.4 (p <0.05), and only slightly to ECM 
exposed to heparanase  at pH 6.8 and 6.4.  Nonactivated T 
cells did not bind  to the intact  ECM,  regardless  of its ex- 
posure to various pH values,  or if the ECM  had not been 
treated  with  heparanase  (Fig.  4  A).  In  contrast,  phorbol 
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Figure 3.  Restoration  of  the  enzymatic  activity  of  ECM-bound 
heparanase in response to a change in pH. Heparanase (0.1/~g/ml) was 
incubated  (2  h,  37~  pH  7.2)  with  3sS-labded  ECM.  Unbound 
heparanase was then removed by washing, and the 35S-ECM plus bound 
heparanase was incubated (24 h, 37~  at pH 6.4 or 7.2. Release of 3ss- 
labeled low molecular weight (peak II) HS degradation  fragments  was 
analyzed by gel filtration on Sephadex 6B. The figure shows one experi- 
ment representative of three. 
Figure 4.  Adhesion of purified human CD4 § T cells to ECM at pH 
7.2. 51Cr-labeled  human CD4 + T cells were added to ECM-coated mi- 
crotiter wells that had been preincubated (2 h, 37~  pH 7.2) with buffer 
or heparanase (0.1/~g/ml), followed by aspiration, washing, and blocking 
with 1% BSA in PBS. (.4) Dependence of heparanase-mediated adhesion 
of T cells to ECM on the pH at which the heparanase was bound to the 
ECM.  Cell binding to the wells was determined  after 30 min at 37~ 
(B) Involvement of integrins in heparanase-mediated binding of T cells 
to ECM. mAbs (15-25/xg/ml) to the human integrins,  VLA-4-6, and 
CD29 (Serotec, Oxford, UK), were added to the ECM-coated wells simul- 
taneously with the T cells. Where indicated, the T cells  were preincubated 
with heparin (10/~g/ml) before seeding into the wells containing ECM 
and ECM-bound heparanase. In A and/3, the results from quadruplicate 
wells are depicted of four experiments. (C) 51Cr-labeled  T cells (2  x  105 
cells) were incubated (2 h, 37~  pH 7.2) with 0.2 ml of Sepharose beads 
(Sb),  heparin-Sb (0.2 ml), or heparanase bound to heparin-Sb (0.2/~g 
heparanase per sample). To measure T cell binding to the beads, the con- 
tents of the tubes were passed through disposable polypropylene columns 
(Pierce Chemical Co., Rockford, IL), which allow the passage of  unbound, 
but not bound, ceils. The columns were washed extensively, and the ra- 
dioactivity associated with the columns was determined. In addition, the 
binding of T cells (2  x  10  s ceils/well) to heparanase-treated (1 #g/well; 
2 h, 37~  pH 7.2) microtiter  wells (polystyrene; Falcon, Oxnard, CA) 
was examined 30 min after cell addition to the plates. The figure shows 
one experiment  representative of four for A-C. 
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binding of T  cells to heparanase-bound ECM was inhibited 
by heparin (Fig. 4 B), which competes with HS for heparanase 
recognition  (6).  Thus,  analogous  to  proteoglycan-bound 
chemokines (3, 16, 23, 24), non-enzymatically active hepara- 
nase can act as a proteoglycan-associated proadhesive mole- 
cule for resting  T  cells. 
T cell recognition of adhesive glycoproteins present in ECM 
is  mediated  primarily  by B1  integrins  (very late  antigens 
[VLA]; 1, 2). Whether the heparanase-induced T cell binding 
to ECM at pH 7.2 involves integrins  was examined in blocking 
experiments with mAb. Adhesion of T cells to ECM to which 
heparanase was bound was partially inhibited by mAb to the 
common/~1  chain  (CD-29)  of the VLA integrins  and by 
mAb to the VLA-4 molecule (p <0.05;  Fig.  4 B).  Hence, 
the heparanase-mediated adhesion of CD4 + T lymphocytes 
to ECM  appears  to involve integrin  binding. 
Whether  the  CD4 §  T  cells  can  interact  directly  with 
heparanase  at physiological pH was assessed by examining 
their adhesion to immobilized heparanase.  T cells bound pref- 
erentially to heparanase  attached to heparin-Sepharose beads, 
but not to intact heparin-Sepharose beads or to heparanase- 
treated microtiter wells (Fig.  4 C).  At pH 6.4,  heparanase 
cleaves the heparin  from the Sepharose beads and thus the 
cell binding to heparin-Sepharose beads could not be assessed 
at this pH. These results suggest that the conformation ac- 
quired by the heparanase  complexed to heparin-like  mole- 
cules or HS in the ECM is accessible for T cell recognition, 
and that pH-dependent conformational changes in heparanase 
may account for its versatile roles. 
Heparanase,  like growth factors, chemokines, and cytokines, 
is  secreted from activated CD4 + T  cells  (2,  12,  25).  The 
secreted heparanase can bind to HS in the ECM and can per- 
form different functional programs,  depending on the local 
conditions.  Our results suggest that at relatively low pH values, 
heparanase,  as a pivotal element of the invading cell's ECM- 
specific enzymatic repertoire, can actively participate in ECM 
degradation,  and thereby facilitates  cell migration.  In fact, 
significant  amounts  of heparanase  have  been  observed in 
inflamed tissues,  such as in synovial fluids of rheumatoid ar- 
thritis patients (Vlodavsky, I. et al.,  manuscript in prepara- 
tion), where the pH values are mildly acidic (26). At a physi- 
ological pH, the relatively quiescent enzyme appears to act 
as a lectin-like proadhesive molecule that  can organize the 
recruitment  of resting  T  cells in extravascular  loci.  There- 
fore, the heparanase-mediated ECM-anchored CD4 + T cells 
could readily respond  to  costimulatory  signals  elicited by 
specifically activated adjacent immune cells. Besides the par- 
ticular relevance of our findings for interactions between im- 
mune cells and the ECM,  the pH-dependent  modification 
of heparanase  function illustrates a general principle that bio- 
logically important  molecules can  adapt  their  behavior to 
context  (27). 
We thank Dr. I. R. Cohen for his invaluable suggestions, and Dr. B. Schick for reviewing the manuscript. 
O. Lider is the incumbent  of the Weizmann League Career Development Chair in Children's Diseases. 
Address correspondence to Dr. O. Lider, The Department  of Cell Biology, The Weizmann  Institute  of 
Science, P.O. Box 26,  Rehovot  76100, Israel. 
Received for publication 19 October 1994 and in revised  form  4January  1995. 
References 
1.  Springer, T.A. 1994. Traffic signals for lymphocyte recircula- 
tion and leukocyte emigration:  the multistep paradigm. Cell. 
76:301-314. 
2.  Adams, D.A., and S. Shaw. 1994. Leukocyte-endothelial inter- 
actions and regulation  of leukocyte migration.  Lancet. 343: 
831-836. 
3.  Tanaka, Y., D.H. Adams, S. Hubscher, H. Hirano, U. Sieben- 
list, and S. Shaw. 1993. T-cell adhesion induced by proteoglycan- 
immobilized cytokine MIP-13.  Nature (Lond.). 361:79-82. 
4.  Vlodavsky, I., A. Eldor, A. Haimovitz-Friedman, Y. Matzner, 
R. Ishai-Michaeli, O. Lider, Y. Naparstek,  I.R. Cohen,  and 
Z. Fuks. 1992. Expression of heparanase by platelets and cir- 
culating cells of the immune system: possible involvement in 
diapadesis and extravasation. Invasion Metastasis. 12:112-123. 
5.  Lider, O., Y.A. Mekori, T. Miller, R. Bar-Tana, I. Vlodavsky, 
E. Baharav, I.R. Cohen, and Y. Naparstek.  1990. Inhibition 
ofT lymphocyte heparanase by heparin prevents T cell migra- 
tion and T cell-mediated immunity. Eur.  J. Immunol. 20:493- 
499. 
6.  Bar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, I.R. Cohen, 
Z.  Fuks, and I. Vlodavsky. 1987. Inhibition  of heparanase- 
mediated degradation  of extracellular matrix heparan sulfate 
by non-anticoagulant  heparin species. Blood. 70:551-557. 
7.  Wrenshall, L.E., F.B. Cerra, A. Carlson, F.H. Bach, andJ.L. 
Platt. 1991. Regulation of murine splenocyte responses by he- 
paran sulfate. J. Immunol. 147:455-459. 
8.  Higashiyama,  S., J.A.  Abraham,  and M.  Klagsbrun.  1993. 
Heparin-binding EGF-like growth factor stimulation of smooth 
muscle cell migration:  dependence on interactions with cell 
surface heparan sulfate. J. Cell Biol. 122:933-939. 
9.  Folkman, J., M. Klagsbrun, J. Jasse, M. Wadzinski, D. Ingber, 
and I. Vlodavsky. 1988. A heparin-binding angiogenic protein- 
basic fibroblast growth factor is stored within basement mem- 
1933  Gilat et al.  Brief  Definitive Report branes.  Am. J. Pathol. 130:493-400. 
10.  Oosta G.M., L.V. Favreau, D.L. Beeler, and K.D. Kosenberg. 
1982. Purifcation and properties of human platelet heparanase. 
J. Biol. Chem.  257:11249-11255. 
11.  Ishai-Michaeli,  g., A. Eldor, and I. Vlodavsky. 1990. Hepara- 
nase activity expressed by platelets, neutrophils and lymphoma 
cells releases active fibroblast growth factor from extracellular 
matrix.  Cell Regul.  1:833-842. 
12.  Fridman, K., O. Lider, Y. Naparstek, Z. Fuks,  I. Vlodavsky, 
and I.R. Cohen. 1986. Soluble antigen induces T lymphocytes 
to secrete an endoglycosidase that degrades the heparan sulfate 
moiety of subendothelial extracellular matrix.J. Cell. Physiol. 
130:85-92. 
13.  Alon, A., L. Cahalon, K. Hershkoviz, B. Reizis,  D. Elbaz, 
D. Wallach, S.K. Akiyama, K.M. Yamada, and O. Lider. 1994. 
TNFot binds to the N-terminal domain of fibronectin and aug- 
ments the 131-integrin-mediated adhesion  of CD4 § T cells to 
this glycoprotein. J. Immunol.  152:1304-1313. 
14.  Hershkoviz, R., L. Cahalon, S. Miron, T. Sapir, R. Alon, S.K. 
Akiyama, K.M. Yamada, and O. Lider. 1994. TNFc~ associated 
with fibronectin enhances PMA or antigen-dependent matrix- 
adhesion of CD4 + T cells via protein tyrosine phosphoryla- 
tion. J. Immunol.  153:554-565. 
15.  Ricoveri, W., and R.  Cappelleti.  1986.  Heparan sulfate en- 
doglycosidase and metastatic potential in murine fibrosarcoma 
and melanoma. Cancer Res. 46:3855-3861. 
16.  Gilat, D., R. Hershkoviz, Y.A. Mekori, I. Vlodavsky, and O. 
Lider. 1994. Regulation of adhesion of CD4 § T lymphocytes 
to intact or heparinase-treated  subendothelial extracellular ma- 
trix by diffusible or anchored MIP-13 and RANTES. J. Im- 
munol.  153:4899-4906. 
17.  Florey, H.W.  1970.  Inflammation. In General Pathology. L. 
Florey, editor. Lloyd-Luke Ltd., London. 23-24. 
18.  Ratner, S.  1992. Motility of IL-2 stimulated lymphocytes in 
neutral  and  acidified  extracellular  matrix.  Cell. Immunol. 
139:399-410. 
19.  Tannock, I.F.,  and D. Kotin.  1989. Acid pH in tumors and 
its potential for therapeutic exploitation. Cancer Res. 49:4373- 
4384. 
20.  Silver, I.A. 1978. Tissue pO2 changes during acute inflamma- 
tion. Adv. Exp.  Med. Biol. 94:769-778. 
21.  Swallow, C.J., S. Grinstein, and O.D. Korstein. 1992. Lipo- 
polysaccharide impairs macrophage cytoplasmatic pH regula- 
tion under conditions simulating the inflammatory microen- 
vironment. J. Leukoc. Biol. 52:395-399. 
22.  Korner, G., T. Bjornsson, and I. Vlodavsky.  1993. Extracel- 
lular matrix produced by cultured corneal and aortic endothelial 
cells contains active tissue-type and urokinase-type plasminogen 
activators. J.  Cell. Physiol. 154:456-463. 
23.  Witt,  D.P.,  and A.D. Lander.  1994. Differential binding of 
chemokines to glycosaminoglycan subpopulation. Cure. Biol. 
4:394-400. 
24.  Taub, D.D., K. Conlon, A.R. Lloyd,  J.J. Oppenheim, and D.J. 
Kelvin.  1993.  Preferential  migration  of  activated  human 
CD4 + and CD8 + T  cells in response to MIP-lc~ and MIP- 
113. Science (Wash. DC).  260:355-358. 
25.  Blotnick, S., G.E. Peoples, M.R. Freeman, T.J. Eberlein, and 
M.  Klagsbrun.  1994. T  lymphocytes synthesize and export 
heparin-binding epidermal growth factor-like and basic fibro- 
blast growth factor, mitogenic for vascular cells and fibroblasts: 
differential  production and release by CD4 + and CD8 § T 
cells. Proc Natl. Acad. Sci. USA.  91:2890-2894. 
26.  Falchuk, K.H., E.G. Goetzl, andJ.P. Kulta. 1970. Respiratory 
gases of synovial fluids: an approach to synovial tissue circula- 
tory-metabolic imbalance in rheumatoid arthritis. Am.J. Med. 
49:223-231. 
27.  Nathan, C., and M. Sporn. 1991. Cytokines in context.J. Cell 
Biol.  113:981-987. 
1934  Heparanase  as an ECM-degrading Enzyme or as a T CeU Adhesion Molecule 